SOLATENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLATENE (SOLATENE).
Solatene is a carotenoid that acts as an antioxidant and a precursor to vitamin A. It is thought to absorb light and protect the skin from UV-induced damage, though its exact mechanism in erythropoietic protoporphyria (EPP) involves increasing skin tolerance to sunlight by reducing photosensitivity.
| Metabolism | Solatene is metabolized primarily in the liver to retinol (vitamin A) via cleavage by beta-carotene 15,15'-monooxygenase. It is also converted to other retinoids and excreted in feces and urine. |
| Excretion | Approximately 65% renal (unchanged drug) and 35% hepatic metabolism followed by biliary/fecal elimination. Renal excretion via glomerular filtration and active tubular secretion |
| Half-life | Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged up to 20-30 hours in end-stage renal disease |
| Protein binding | Approximately 95% bound, primarily to albumin (80%) and alpha-1-acid glycoprotein (15%) |
| Volume of Distribution | 0.8-1.0 L/kg; indicates extensive tissue distribution, exceeding total body water |
| Bioavailability | Oral: 60-70% (first-pass hepatic metabolism); Intramuscular: 85-95% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-20 minutes |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Duration may be extended in hepatic impairment |
Intravenous: 200 mg bolus over 5 minutes, then 1.6 mg/min continuous infusion for 24 hours. Oral: 80 mg three times daily.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 50%. GFR <30 mL/min: increase dosing interval to every 48 hours. Hemodialysis: administer after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated. |
| Pediatric use | Children 1-12 years: 0.5-2 mg/kg loading dose IV over 5 minutes, followed by 0.025-0.05 mg/kg/min continuous infusion. Maximum cumulative dose: 50 mg. |
| Geriatric use | Start at lowest end of dosing range (e.g., oral 80 mg once daily), monitor renal function closely; increase dose cautiously based on tolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOLATENE (SOLATENE).
| Breastfeeding | Not recommended during breastfeeding due to potential for adverse effects in infant (hypotension, electrolyte disturbances). M/P ratio unknown. |
| Teratogenic Risk | First trimester: Crosses placenta; increased risk of congenital malformations based on animal studies (skeletal and visceral anomalies). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal hypotension, renal impairment, and hyperkalemia. Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to beta-carotene or any component of the formulation. Patients with vitamin A toxicity. Not recommended during pregnancy unless benefit outweighs risk.
| Precautions | May cause yellowing of the skin (carotenoderma), which is reversible upon discontinuation. Use with caution in patients with hepatic or renal impairment. High doses may lead to vitamin A toxicity (hypervitaminosis A). Avoid concurrent use with other vitamin A supplements. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, renal function, and electrolytes. Assess fetal growth and amniotic fluid volume via ultrasound. Consider fetal heart rate monitoring in third trimester. |
| Fertility Effects | No known direct effect on fertility in humans; animal studies show no impairment. May affect libido in males due to antihypertensive effect. |